A recent study reveals that people who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt conventional lifestyle programs.
Findings released in a major medical journal demonstrates that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these drugs must be cognizant of the danger of rapid weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of regain implies a reversion to starting mass within about 18 months.
Weighing Approaches
The study, which examined dozens of studies involving thousands of participants, contrasted the results of these new drugs with older methods.
Scientists emphasize that people who lose weight through dieting usually have a more gradual creep back—perhaps 100 grams monthly—after stopping.
Explaining the Quick Regain
Experts suggest the way of the jabs explains the amplified regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than normal might result in the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making overeating much more probable."
A Lifelong Condition?
Health authorities advise the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts say that, due to the likelihood of relapse, the therapy might need to be life-long.
This view is supported by pharmaceutical companies, who state that the results "underscore the persistent nature of obesity," comparing it to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the medication describe a powerful return of hunger.
"I experienced a switch that goes on and you become extremely hungry," described a patient.
This challenge is compounded if users have not developed permanent lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while the jabs are effective tools for weight loss, they are not a permanent solution and maintained weight loss hinges on combined behavioural support.
